The tumour form multiple myeloma is very challenging to treat and is still considered incurable. In a recently published study in the scientific journal Oncotarget, researchers at Uppsala University show how inhibition of ...
Oct 27, 2017
0
1
It's a cancer of the plasma cells, which normally make an array of antibodies that protect us from infection.
Aug 10, 2017
0
1
An Australian-led research team has demonstrated a new therapeutic approach that can re-build and strengthen bone, offering hope for individuals with the debilitating bone cancer, multiple myeloma.
Jun 29, 2017
0
0
Doctors are reporting unprecedented success from a new cell and gene therapy for multiple myeloma, a blood cancer that's on the rise. Although it's early and the study is small—35 people—every patient responded and all ...
Jun 5, 2017
0
1512
In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy ? chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or ...
Jun 5, 2017
0
2
Researchers from Belgium led by Prof. Dirk Elewaut of the VIB-UGent Center for Inflammation Research and the team of Prof. Vanderkerken and Prof. Menu at the Hematology and Immunology lab of the VUB uncovered a new way to ...
Jun 1, 2017
0
0
A compound identified by Weill Cornell Medicine scientists inhibits the growth of a rare blood cancer found in people with HIV-AIDS. Their research, published May 15 in the Journal of Clinical Investigation, also demonstrates ...
May 17, 2017
0
221
(HealthDay)—Combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) plus stem-cell transplantation is associated with longer progression-free survival than RVD alone for adults with multiple myeloma, ...
Apr 7, 2017
0
2
Multiple myeloma is a cancer of the plasma cells, which are white blood cells produced in bone marrow that churn out antibodies to help fight infection. When plasma cells become cancerous, they produce abnormal proteins, ...
Apr 4, 2017
0
68
Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by multiple myeloma. The findings are published in Nature Medicine.
Mar 8, 2017
0
2
